ISPOR 2018
May 19-23, 2018
Baltimore Convention Center
Baltimore, MD, USA
Program
» Search the meeting program and create your personalized schedule
» myISPORBaltimore
(Program subject to change)
Program Tuesday, May 22, 2018
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Chief Science Officer, ISPOR - The Professional Society for Health Economics and Outcomes Research, Lawrenceville, NJ, USA
Director, Health Technology Assessment and Health Economics Department, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina
Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
Assistant Professor, School of Pharmacy and Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, Los Angeles, CA, USA
Professor, Centre for Health Economics, University of York, York, UK
Professor, Health Services Research and Health Technology Assessment, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
There is increasing availability and use of digital technologies such as smart phones, social media platforms, and wearables that potentially allow for significant increases in participation in both health-related research and general tracking of health metrics. This session will provide a balanced overview of where there is reliable evidence that digital technologies have improved health and where there is mainly hype. The session will address the following questions:
• Does the empirical evidence confirm that digital health has actually improved public health?
• What evidence is there regarding the global impact of digital health on research?
• Has digital health helped to close health disparities’ gaps?
• What are ethical concerns surrounding tracking health data and how are they being managed?
Professor & Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
Network Director Venture Investments, University of Vermont Health Network, Burlington, VT, USA
Chief Executive Officer & Founder, Access Healthcare Foundation, Rockville, MD, USA
Assistant Professor, Pediatrics, Institute of Human Virology and University of Maryland School of Medicine, and Senior Technical Advisor, Pediatric and Adolescent HIV, Department of Prevention, Care and Treatment and International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria
|
IP8: HOW IMPORTANT ARE CORE OUTCOME SETS TO MEASURING VALUE OF INNOVATIVE NEW DRUGS? |
|
| Moderator: |
Elise Berliner, PhD, Director, Technology Assessment Program, Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Rockville, MD, USA |
| Panelists: |
Chuck Shih, PhD, MHS, Associate Director, Healthcare Reform & Public Policy, Biogen, Washington, DC, USA Elizabeth Seeley, MS, PhD, Adjunct Lecturer on Health Policy and Management, Department of Health Policy and Management, TH Chan School of Public Health, Harvard University, Boston, MA, USA Sean R Tunis, MD, MSc, President and Chief Executive Officer, Center for Medical Technology Policy, Baltimore, MD, USA |
| Moderator: |
Neil Hawkins, PhD, Professor of Health Technology Assessment (HTA), Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK |
| Panelists: |
Renée J G Arnold, PharmD, Director, Life Sciences, Navigant Consulting, Inc., San Francisco, CA, USA J. Jaime Caro, MDCM, Adjunct Professor, Medicine, Epidemiology, and Biostatistics, McGill University, Montreal, QC, Canada |
| W9: NUMBERS OR NOISE? INTERPRETING INTERNAL VALIDITY TESTS OF STATED-PREFERENCE DATA | |
| Discussion Leaders: |
Kathryn O’Callaghan, PhD, Assistant Director of Strategic Programs, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA F. Reed Johnson, PhD, Professor, Population Health Sciences, School of Medicine, Duke University, Durham, NC, USA Kevin Marsh, PhD, Executive Director, Outcomes Research, Evidera Ltd, London, UK Jui-Chen Yang, MEM, Research Economist, Preference Evaluation Research Group, Duke Clinical Research Institute, Durham, NC, USA |
| W10: MILLION DOLLAR THERAPIES FOR RARE CONDITIONS: RETHINKING VALUE | |
| Discussion Leaders: |
Louis P. Garrison, PhD, Professor Emeritus, The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA Clifford Goodman, PhD, Senior Vice President and Director, Center for Comparative Effectiveness Research, The Lewin Group, Falls Church, VA, USA Paul Melmeyer, MPP, Director of Federal Policy, National Organization for Rare Disorders (NORD), Washington, DC, USA |
| W11: CHOOSING THE APPROPRIATE MODELING METHOD: CAUSAL MODELING, HEALTH ECONOMIC MODELING, CONSTRAINED OPTIMIZATION OR SIMULATION? | |
| Discussion Leaders: |
William H Crown, PhD, Chief Scientific Officer, OptumLabs, Cambridge, MA, USA Praveen Thokala, MASc, PhD, Research Fellow, The University of Sheffield, Sheffield, UK Deborah A Marshall, PhD, Professor, University of Calgary, Calgary, AB, Canada Kalyan S. Pasupathy, PhD, Faculty, Healthcare Policy & Research and Co- Scientific Director, Healthcare Systems Engineering Program, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA |
Senior Director HEOR, Astra Zeneca, Gaithersburg, MD, USA
CN1
11:00 AM - 11:15 AMECONOMIC GUIDANCE PANEL CHANGES TO MINIMIZE POST-PROGRESSION TREATMENT EFFECTS BY THE PAN-CANADIAN ONCOLOGY DRUG REVIEW IN ECONOMIC EVALUATIONS ASSESSING CANCER DRUGS
Samjoo I, Whitney S, Grima A, Grima DCornerstone Research Group, Burlington, ON, Canada
CN2
11:15 AM - 11:30 AMESTIMATING THE IMPACT OF AFFORDABLE CARE ACT (ACA) ON LIKELIHOOD OF RECEIVING MAMMOGRAPHY AND PAP SMEAR SCREENINGS
Alharbi A, Khan MMUniversity of South Carolina, Columbia, SC, USA
CN3
11:30 AM - 11:45 AMHEALTH-RELATED QUALITY OF LIFE ASSESSMENTS PREDICT RELAPSE OR DEATH IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE CONNECT® MM REGISTRY
Wagner I1, Durie BG2, Jagannath S3, Narang M4, Terebelo HR5, Gasparetto C6, Toomey K7, Hardin JW8, Kitali A9, Yue L9, Agarwal A9, Srinivasan S9, Flick ED9, Rifkin RM10, Abonour R111Wake Forest University School of Medicine, Winston-Salem, NC, USA, 2Cedars-Sinai Samuel Oschin Cancer Institute, Los Angeles, CA, USA, 3Mount Sinai Hospital, New York, NY, USA, 4Maryland Oncology Hematology, Columbia, MD, USA, 5Providence Hospital and Medical Center, Southfield, MI, USA, 6Duke Cancer Institute, Durham, NC, USA, 7Steeplechase Cancer Center, Somerville, NJ, USA, 8University of South Carolina, Columbia, SC, USA, 9Celgene Corporation, Summit, NJ, USA, 10US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO, USA, 11Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA
CN4
11:45 AM - 12:00 PMPROJECTING OVERALL SURVIVAL (OS) WITH IMMUNO-ONCOLOGY (IO) TREATMENTS: APPLICATION OF ALTERNATIVE APPROACHES IN METASTATIC MERKEL CELL CARCINOMA (MMCC)
Proskorovsky I1, Lanitis T2, Ambavane A2, Hunger M3, Bharmal M4, Zheng Y5, Phatak H51Evidera, Montreal, QC, Canada, 2Evidera, London, UK, 3Mapi, an ICON plc company, Munich, Germany, 4Merck KGaA, Darmstadt, Germany, 5EMD Serono Inc., Rockland, MA, USA
Managing Director, Novosys Health, Green Brook, NJ, USA
CV1
11:00 AM - 11:15 AMNON-INFERIORITY CLINICAL TRIAL DESIGN, DRUG APPROVAL, AND IMPLICATIONS FOR CLINICIANS IN PRESCRIBING ORAL ANTICOAGULANTS
Choi YC1, Vo TN1, Carlson AM21University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA
CV2
11:15 AM - 11:30 AMSECONDARY PREVENTION USING CHOLESTEROL-LOWERING MEDICATIONS IN PATIENTS MEETING NEW TREATMENT GUIDELINES: A RETROSPECTIVE COHORT ANALYSIS
Han X1, McCombs JS1, Fox DS1, Chu M1, Dougherty JS21University of Southern California, Los Angeles, CA, USA, 2PhRMA, Washington, DC, USA
CV3
11:30 AM - 11:45 AMCOMPARATIVE EFFECTIVENESS OF DIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
Done N1, Li D1, Woolley A2, Rose AJ3, Prentice JC11Veterans Health Administration, Boston, MA, USA, 2Bouve College of Health Sciences, Boston, MA, USA, 3RAND Corporation, Boston, MA, USA
CV4
11:45 AM - 12:00 PMADHERENCE TO SELF-CARE RECOMMENDATIONS AND ASSOCIATED FACTORS AMONG ADULT HEART FAILURE PATIENTS AT GONDAR UNIVERSITY REFERRAL HOSPITAL, NORTHWEST ETHIOPIA.
Seid MAUniversity of Gondar, Gondar, Ethiopia
| Moderator: |
Jalpa A. Doshi, PhD, Professor of Medicine, Perelman School of Medicine; Director, Economic Evaluations Unit, Center for Evidence-based Practice; Director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA |
| Panelists: |
Steven Miller, MD, MBA, Senior Vice President and Chief Medical Officer, Express Scripts, St. Louis, MO, USA Cat Davis Ahmed, MBA, Vice President, Policy and Outreach, The FH Foundation, Pasadena, CA, USA Seth J. Baum, MD, President, Affiliate Professor of Medicine, Schmidt College of Medicine, Florida Atlantic University (FAU), American Society for Preventive Cardiology; Chief Medical Officer, Excel Medical Clinical Trials, Boca Raton, FL, USA |
| Moderator: |
Guru Madhavan, PhD, MBA, Senior Program Officer, Health and Medicine, National Academies of Science, Engineering, and Medicine, Washington, DC, USA |
| Panelists: |
Norman Augustine, MS, Retired, Lockheed Martin Corporation, Bethesda, MD, USA Charles E. Phelps, PhD, MBA, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Rochester, NY, USA Stacie B. Dusetzina, PhD, Associate Professor, Health Policy, Ingram Associate Professor of Cancer Research, Vanderbilt University Medical Center, Nashville, TN, USA Robert W. Dubois, MD, PhD, Chief Science Officer & Executive Vice President, National Pharmaceutical Council, Washington, DC, USA |
| W12: COMPLEX REAL-WORLD EVIDENCE: NETWORKED AND MISSING DATA | |
| Discussion Leaders: |
Laura Hatfield, PhD, Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA Sherri Rose, PhD, Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA Alisa Stephens-Shields, PhD, Assistant Professor, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA Amanda Mejia, PhD, Assistant Professor, Department of Statistics, Indiana University, Bloomington, IN, USA |
| Moderator: |
John Watkins, PharmD, MPH, Pharmacy Manager, Formulary Development, Premera Blue Cross, Mountlake Terrace, WA, USA |
| Panelists: |
Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK Steven D. Pearson, MD, MSc, Founder and President, Institute for Clinical and Economic Review, Boston, MA, USA Carleigh B Krubiner, PhD, Research Scholar and Project Director, Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA |
| Moderator: |
Jipan Xie, MD, PhD, Vice President, Analysis Group, Inc., New York, NY, USA |
| Panelists: |
Yiduo Zhang, PhD, Director, Health Economics and Payer Analytics, Global Payer Evidence and Pricing, AstraZeneca, Gaithersburg, MD, USA Russell Hales, MD, Director, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA Louis P. Garrison, PhD, Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy University of Washington, Seattle, WA, USA |
| Moderator: |
Kathryn A. Phillips, PhD, Professor, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California – San Francisco, San Francisco, CA, USA |
| Panelists: |
Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research, Professor, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Dean A. Regier, PhD, Scientist, Canadian Centre for Applied Research in Cancer Control (ARCC), British Columbia Cancer Agency, Vancouver, BC, Canada Sarah Wordsworth, PhD, Associate Professor, Nuffield Department of Population Health, University of Oxford, Oxford, UK |
| W13: WHAT IS PATIENT-CENTERED AND FIT-FOR-PURPOSE PATIENT PREFERENCE INFORMATION? | |
| Discussion Leaders: |
Stephanie Christopher, MA, Program Director, Medical Device Innovation Consortium, Arlington, VA, USA Anindita Saha, BSE, Director, External Expertise and Partnerships, Center for Devices & Radiological Health (CDRH), US Food & Drug Administration, Silver Spring, MD, USA A. Brett Hauber, PhD, Senior Economist & Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA Margaret Sheehan, JD, Patient Council, The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA |
| W14: NETWORK META-ANALYSIS FOR VARIOUS STUDY DESIGNS: STEPPING OUTSIDE THE RANDOMIZED CONTROLLED TRIALS COMFORT ZONE INTO THE REAL WORLD | |
| Discussion Leaders: |
Christopher Schmid, PhD, Professor of Biostatistics, School of Public Health, Brown University, Providence, RI, USA Ashley Pitcher, BSc, DPhil, Engagement Manager, IQVIA, London, UK Andreas Karabis, PhD, Principal, RWI, IQVIA, Amsterdam, The Netherlands |
HT1
3:45 PM - 4:00 PMSIMILARITIES AND DIFFERENCES IN EUROPEAN HTA EVIDENCE REQUIREMENTS: ONE FOR ALL OR ONE FOR NONE?
Mordin M1, Fernandez MM2, Pearson I3, Copley-Merriman C1, McBride D31RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3RTI Health Solutions, Manchester, UK
HT2
4:00 PM - 4:15 PMA HOLISTIC APPROACH TO EVALUATE THE COST-EFFECTIVENESS OF PEMBROLIZUMAB WITH MULTIPLE INDICATIONS: A NORWAY-BASED EXAMPLE
Wu E1, Pellissier J2, Kvamme M3, Irgens K31Merck, North Wales, PA, USA, 2Merck & Co., Inc., North Wales, PA, USA, 3MSD Norge A/S, Drammen, Norway
HT3
4:15 PM - 4:30 PMUSING REAL-WORLD EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS: LESSONS AND INSIGHTS FROM REVIEW OF NICE’S TECHNOLOGY ASSESSMENT REPORTS (2016-2017)
Aggarwal S1, Topaloglu O1, Kumar S21NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA
HT4
4:30 PM - 4:45 PMHEALTH TECHONOLGY ASSESSMENT (HTA) AGENCIES CONSIDERATION OF REAL WORLD EVIDENCE (RWE)
Jao R1, Jaksa A1, Pontynen A1, Wang X21Context Matters, New York, NY, USA, 2Celgene Corporation, Summit, NJ, USA
Associate Professor, University of Maryland School of Pharmacy, Baltimore, MD, USA
HU1
3:45 PM - 4:00 PMANNUAL CHANGE IN CONTROLLED SUBSTANCE OPIOID PRESCRIBING AND CONCOMITANT MEDICATIONS FROM AN URBAN ACADEMIC EMERGENCY DEPARTMENT FROM 2011 – 2016
Voelker J1, Crawford A1, Sabonjian M2, Maio V3, Mammen P21Jefferson College of Population Health at Thomas Jefferson University, Philadelphia, PA, USA, 2Thomas Jefferson University Hospital, Philadelphia, PA, USA, 3Thomas Jefferson University, Philadelphia, PA, USA
HU2
4:00 PM - 4:15 PMCOGNITIVE DECLINE WITH ANTICHOLINERGIC MEDICATION USE AMONG ELDERLY NURSING HOME RESIDENTS WITH DEPRESSION
Aparasu RR1, Chatterjee S2, Johnson ML3, Chen H3, Carnahan R41Department of Pharmaceutical Health Outcomes and Policy, Houston, TX, USA, 2Novartis Healthcare Pvt Ltd, Hyderabad, India, 3College of Pharmacy, University of Houston, Houston, TX, USA, 4University of Iowa, Iowa City, IA, USA
HU3
4:15 PM - 4:30 PMINITIATION OF PSYCHOTROPIC PRESCRIPTIONS WITHOUT A PSYCHIATRIC DIAGNOSIS IN US ADULTS
Rhee TG1, Rosenheck RA21Yale University School of Medicine, New Haven, CT, USA, 2Yale University School of Medicine, West Haven, CT, USA
HU4
4:30 PM - 4:45 PMTHE USE OF MACHINE LEARNING TO BOOST IDENTIFICATION OF ATRIAL FIBRILLATION AND INCREASE APPROPRIATE UTILIZATION OF ANTICOAGULANT DRUGS
Hertzberg J, Forni AOptum, Minnetonka, MN, USA
|
IP15: HOW CAN WE ADDRESS THE CURRENT CHALLENGES IN VALUE ASSESSMENT? |
|
| Moderator: |
Sachin Kamal-Bahl, PhD, VP & Head, Center for Health Systems Innovation & Leadership, Pfizer, Inc., New York, NY, USA |
| Panelists: |
Josh J. Carlson, MPH, PhD, Associate Professor, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA Shelby D Reed, PhD, RPh, Professor in Medicine, Preference Evaluation Research Group, Duke Clinical Research Institute, Durham, NC, USA Gillian D Sanders Schmidler, PhD, Deputy Director, Academics and Professor of Population Health Sciences, School of Medicine, The Robert J. Margolis, MD, Center for Health Policy, Duke University, Washington, DC, USA |
|
IP16: IN THE ELECTRONIC HEALTH RECORD ERA, DO WE STILL NEED CLINICAL REGISTRIES? |
|
| Moderator: |
Lisa M. Wruck, PhD, Director, Center for Predictive Medicine, Duke Clinical Research Institute, Durham, NC, USA |
| Panelists: |
Sharon Hensley Alford, PhD, Associate Chief Health Officer, IBM Watson Health, Cambridge, MA, USA Marc Berger, MD, Consultant, Self Employed, New York, NY, USA Tracy Wang, MD, MHS, Associate Professor of Medicine, Duke Clinical Research Institute, Duke School of Medicine, Durham, NC, USA |
| Moderator: |
Rok Hren, PhD, MSc, Assistant Professor, University of Ljubljana, Ljubljana, Slovenia |
| Panelists: |
Katarzyna Kolasa, PhD, Professor of Health Economics, Head of Department, Health Economics and Healthcare Management, Kozminski University, Warszawa, Poland Rosanna Tarricone, Associate SDA Dean, Government, Health and Non Profit Division, Centre for Research on Health and Social Care Management (CeRGAS), SDA Bocconi School of Management, Milan, Italy Cynthia Iglesias, PhD, Senior Research Fellow, Centre for Health Economics, University of York, York, UK |
| W15: PATIENT INVOLVEMENT THROUGHOUT THE STAGES OF PATIENT-REPORTED OUTCOME DEVELOPMENT AND CLINICAL TRIAL IMPLEMENTATION | |
| Discussion Leaders: |
Sarah L Knight, BSc, MSc, Consultant, Clinical Outcomes Assessment Team, DRG Abacus, Bicester, UK Helen Kitchen, MSc, Senior Consultant, Clinical Outcomes Assessment, DRG Abacus, Manchester, UK Ann Hartry, PhD, Vice President, Health Economics and Outcomes Research (HEOR), Lundbeck, Deerfield, IL, USA Cindy Coney, M.Ed, BSc, President, and Patient Advocate, Monarch Training and Consulting, Tampa, FL, USA |
| W16: CHOOSING HOW TO CHOOSE: COLLECTIVE DECISION MAKING IN HEALTHCARE ORGANIZATIONS | |
| Discussion Leaders: |
Charles E. Phelps, PhD, MBA, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Rochester, NY, USA Guru Madhavan, PhD, MBA, Senior Program Officer, Health and Medicine, National Academies of Science, Engineering, and Medicine, Washington, DC, USA |
Assistant Professor, University of Maryland School of Pharmacy, Baltimore, MD, USA
AD1
5:00 PM - 5:15 PMTHE ASSOCIATION BETWEEN ANTI-EPILEPTIC DRUG ADHERENCE TO SODIUM CHANNEL BLOCKERS AND HEALTH-RELATED QUALITY OF LIFE: ANALYSIS OF US SURVEY DATA FROM PATIENTS WITH EPILEPSY
Lee LK1, Rajagopalan K21Kantar Health, San Mateo, CA, USA, 2Sunovion Pharmaceuticals Inc., Marlborough, MA, USA
AD2
5:15 PM - 5:30 PMMODIFIED DRUG ADHERENCE WORK-UP (M-DRAW) TOOL IN PATIENTS WITH DIABETES AT VETERANS AFFAIRS HEALTH SYSTEM: TOOL VALIDATION AND PRELIMINARY RESULT
Lee S1, Gogineni H1, Bae-Shaaw Y2, Worley M3, Law A11Western University of Health Sciences, Pomona, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3Ohio State University, Columbus, OH, USA
AD3
5:30 PM - 5:45 PMADHERENCE ISSUES IN FIBROMYALGIA: HOW CAN ACCEPTANCE MEASUREMENT HELP UNDERSTANDING PATIENTS' CONCERNS AND WORKING ON SOLUTIONS?
Wiederkehr S1, de Bock E1, Chekroun M2, Arnould B11Mapi, An ICON plc Company, Patient-Centered Outcomes, Lyon, France, 2Carenity, Paris, France
AD4
5:45 PM - 6:00 PMDISCONTINUATION, SWITCHING AND RESTARTING AMONG MIGRAINE PATIENTS INITIATING PROPHYLAXIS
Bonafede MM1, Wilson KL1, Xue F2, Chia VM3, Porter JK4, Desai P21Truven Health Analytics, an IBM Company, Cambridge, MA, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen Inc, Thousand Oaks, CA, USA, 4Amgen (Europe) GmbH, Zug, Switzerland
Executive Director, Health Economics, Pharmerit International, Bethesda, MD, USA
AV1
5:00 PM - 5:15 PMCOST-EFFECTIVENESS OF STAGED DIRECT-ACTING ANTIVIRAL TREATMENT POLICIES IN AN INTEGRATED HEALTHCARE SYSTEM
Karmarkar T1, Gaskin DJ1, Rodriguez CV2, Padula WV11Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Kaiser Permanente, Rockville, MD, USA
AV2
5:15 PM - 5:30 PMCOST-EFFECTIVENESS ANALYSIS OF BASELINE TESTING FOR RESISTANCE-ASSOCIATED POLYMORPHISMS TO OPTIMISE TREATMENT DURATION IN GENOTYPE 1 NON-CIRRHOTIC TREATMENT-NAÏVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS
Fawsitt CG1, Vickerman P1, Cooke G2, Welton NJ11University of Bristol, Bristol, UK, 2Imperial College London, London, UK
AV3
5:30 PM - 5:45 PMDOLUTEGRAVIR AND RILPIVIRINE TO TREAT VIROLOGICALLY SUPPRESSED ADULTS LIVING WITH HIV-1: A CANADIAN COST-UTILITY ANALYSIS
Arthurs E1, Ward T2, Darlington O2, Sugrue D2, Martin AA3, Cartier SE4, Lee A4, Becker DL4, Punekar YS5, McEwan P21GSK, Mississauga, ON, Canada, 2Health Economics & Outcomes Research Ltd, Cardiff, UK, 3GSK, Uxbridge, UK, 4Optum, Burlington, ON, Canada, 5ViiV Healthcare, Brentford, Middlesex, UK
AV4
5:45 PM - 6:00 PMCOST-EFFECTIVENESS ANALYSIS OF UNIVERSAL VS TARGETED HUMAN IMMUNODEFICIENCY VIRUS (HIV) SCREENING APPROACHES TO IDENTIFY NEW HIV DIAGNOSES IN THE EMERGENCY DEPARTMENT (ED)
Batista AE1, Bartolome L1, Nelson F2, Maio V1, Mammen P21Thomas Jefferson University, Philadelphia, PA, USA, 2Thomas Jefferson University Hospital, Philadelphia, PA, USA
| F6: VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS EMERGING GOOD PRACTICES TASK FORCE: FINAL RECOMMENDATIONS | |
| Moderator: |
Rachael Fleurence, PhD, Executive Director, National Evaluation System for Health Technology Coordinating Center (NESTcc), Medical Device Innovation Consortium (MDIC), Arlington, VA, USA |
| Speakers: |
Lotte Steuten, PhD, MSc, Associate Professor & Director, Health Economics, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Anirban Basu, PhD, Stergachis Family Endowed Professor & Director, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA Gillian D Sanders Schmidler, PhD, Deputy Director, Academics and Professor of Population Health Sciences, School of Medicine, The Robert J. Margolis, MD, Center for Health Policy, Duke University, Washington, DC, USA James F. Murray, PhD, Research Fellow, Global Health Outcomes - COE, Eli Lilly and Company, Carmel, IN, USA |
| F7: ENABLING ISPOR MEMBER AND PATIENT ADVOCACY GROUP RESEARCH COLLABORATION: A VOLUNTEER PLAN | |
| Moderator: |
Richard J. Willke, PhD, Chief Science Officer, ISPOR, Lawrenceville, NJ, USA bio |
| Speakers: |
Laura T. Pizzi, PharmD, MPH, Professor and Director, Center for Health Outcomes Policy and Economics, Rutgers University, Piscataway, NJ, USA Jason Harris, BA, Associate Director of Policy and Programs, National Health Council, Washington, DC, USA Brian Ung, PharmD, MS, Post-Doctoral Fellow, US Health Economics and Outcomes Research, Celgene Corporation, Summit, NJ, USA |
| F8: REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC? | |
| Moderator: |
Jitendar Sharma, PhD, CEO, Andhra Pradesh MedTech Zone Limited, Andhra Pradesh, India |
| Speakers: |
Sukyeong Kim, PhD, Senior Research Fellow, Evidence-based Research Department, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South) Makoto Kobayashi, PhD, M.Eng., Director and COO, CRECON Medical Assessment Inc., Tokyo, Japan Chee-Jen Chang, PhD, Professor and Director, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City, Taiwan Jianwei Xuan, MD, PhD, Director, Health Economic Research Institute, School of Pharmacy, Sun Yat-Sen University, Guangzhou, China |
| F9: NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS | |
| Moderator: |
Juan Carlos Alandete Manotas, MD, MSc, MPH, MACS LATAM, Bayer, Whippany, NJ, USA |
| Speakers: |
Louis Garrison, PhD, Professor Emeritus, CHOICE Institute, University of Washington, Seattle, WA, USA Ramiro E. Gilardino, MD, MSc, Director, Global Networks Latin America, ISPOR, Lawrenceville, NJ, USA Boxiong Tang, MD, PhD, Senior Director, Global Health Economics and Outcomes Research (GHEOR), Teva Pharmaceutical, Frazer, PA, USA |
Join us for an evening of networking, light bar bites, and live music at the ISPOR Social Event at Tin Roof Baltimore. Known as the “Live Music Joint, where Everybody is Somebody,” Tin Roof offers a fun, inviting, eclectic, laid-back atmosphere. Conveniently located in Baltimore’s popular Power Plant Live and only 1 block away from the world famous Downtown Inner Harbor. So whether you are coming to dance or to grab a drink, this is the perfect opportunity to reconnect with your ISPOR peers! Separate registration required.